Serum SARS-CoV-2 Neutralization Activity
- Funded by University of Minnesota
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19start year
-99Known Financial Commitments (USD)
$0Funder
University of MinnesotaPrincipal Investigator
MD. Tyler BoldResearch Location
United States of AmericaLead Research Institution
Medical School, University of MinnesotaResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The U.S. government has tasked America's universities to develop assays that detect anti-SARS-CoV-2 antibodies in the blood. These tests can define the scope of a population's exposure to SARS-CoV-2 virus, and also identify individuals who may have protective immunity against re-infection. Those with anti-viral antibodies can also donate potentially protective convalescent plasma/serum. "To fully interpret the results of antibody tests, we need a better understanding of whether the antibodies induced by COVID-19 will confer immune protection against subsequent infection with SARS-CoV-2," said Tyler Bold, MD, PhD, assistant professor, Department of Medicine, who is leading this study. "We will use our existing expertise working with BSL3 pathogens to develop a SARS-CoV-2 live viral neutralization assay, that can be used to quantitatively test sera for anti-viral neutralization activity."